Document is current
Any future updates will be listed below
-
Authors
Furusawa-Nishii, Emi
Solongo, Bataa
Rai, Kou
Yoshikawa, Soichiro
Chiba, Asako
Okuzumi, Ayami
Ueno, Shin-ichi
Hoshino, Yasunobu
Imamichi-Tatano, Yoko
Kimura, Haruka
Hatano, Taku
Hattori, Nobutaka
Miyake, Sachiko
-
Funding
Funding for this research was provided by:
Program for Women Researchers from Juntendo University in 2023, and the “Initiative for Realizing Diversity in the Research Environment
the Japan Agency for Medical Research and Development (21wm0425015, 22dm0207070s0204)
the Visionary Council on the Moonshot Research and Development Program (JPMJMS2024-6)
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 26 January 2025
First Online: 11 February 2025
Declarations
:
: This study was approved by the Ethics Committee of Juntendo University (no. 2021100). Written informed consent was obtained from all participants before enrollment.
: Not applicable.
: Outside of the submitted work, NH received grants from Asahi Kasei Medical Co., Ltd., SNBL, Ltd., FP Corp., and Eisai Co., Ltd.; funds for contract research from Cell Source Co., Ltd., MJFF, and MDS; and reports donations to the department, endowed research departments, and joint collaborative research departments from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sunwels Co., Ltd., Eisai Co., Ltd., Nihon Medi-physics Co., Ltd., Abbott Japan LLC, AbbVie GK, Medtronic, Inc., Boston Scientific Japan K.K., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Zebra Co., Ltd., Kowa Co., Ltd., Parkinson Laboratories Co., Ltd., and Ohara Pharmaceutical Co., Ltd.
